Upstream Bio, Inc. UPB
1.59 USD -0.41 (-20.50%)
Regular-session close
1.59 0.00 0.00%
After hours · Nov 20, 4:00 PM ET
1.56 Day range 2.06
1.56 52-week range 33.68
- YTD
- -94.14%
- 1 year
- -93.63%
5D -0.94 (-31.02%)
- Market cap
- 87.15M
- Revenue (ttm)
- 2.85M
- EPS (ttm)
- -3.01
- Shares out
- 54.04M
- Forward P/E
- -2.45
- YTD return
- -94.14%
- 1-year return
- -93.63%
- 50-day average
- 18.55
- Volume
- 1.39M
- Avg volume
- 993.16K
- Open
- 1.98
- Previous close
- 2.00
- Day's range
- 1.56 – 2.06
- 52-week range
- 1.56 – 33.68
- Analysts
- Strong Buy
- Price target
- 47.86 (+2909.9%)
Key statistics
- 200-day average
- 19.11
- Price / sales
- 164.16
- Price / book
- 1.38
- Revenue growth
- 9.00%
- Total cash
- 341.51M
- Total debt
- 1.27M
- Return on equity
- -35.44%
- Short % of float
- 15.85%
Fundamental scorecard
4 of 25 checks passed on UPB’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
UPB Revenue — quarterly 395.00K
UPB Net income — quarterly -41.19M
UPB EPS — quarterly -0.75
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 27, 2026 | Evercore ISI Group | down | Outperform | In-Line |
| Dec 18, 2025 | Mizuho | init | — | Outperform |
| Dec 2, 2025 | LifeSci Capital | init | — | Outperform |
| Nov 18, 2025 | Evercore ISI Group | init | — | Outperform |
| Oct 14, 2025 | Truist Securities | init | — | Buy |
| Nov 5, 2024 | JP Morgan | init | — | Overweight |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- upstreambio.com
News
Your note
Sign in to keep a note on UPB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AI UPSTREAM LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 14, 2024 | 0 |
| AMBROSE ALLISON | General Counsel | Sale | Mar 15, 2026 | 16,525 |
| CHIMOVITS EREZ | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 14, 2024 | 0 |
| DEYKIN AARON M.D. | Officer | Sale | Mar 15, 2026 | 32,687 |
| GRAY MICHAEL P | Chief Operating Officer | Sale | Mar 15, 2026 | 29,648 |
| HOUGHTON ADAM | Officer | Sale | Mar 15, 2026 | 24,301 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.91% | 7,518,202 | 65.18M | Dec 30, 2025 |
| Orbimed Advisors LLC. | 10.54% | 5,693,589 | 49.36M | Dec 30, 2025 |
| Blackrock Inc. | 6.19% | 3,344,504 | 29.00M | Dec 30, 2025 |
| Decheng Capital LLC | 5.82% | 3,143,078 | 27.25M | Dec 30, 2025 |
| NORGES BANK | 5.33% | 2,882,647 | 24.99M | Dec 30, 2025 |
| Enavate Sciences Gp, LLC | 4.55% | 2,459,703 | 21.33M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 1,443,025 | 12.51M | Dec 30, 2025 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.54% | 1,371,372 | 11.89M | Dec 30, 2025 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.48% | 800,000 | 6.94M | Jan 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.44% | 780,261 | 6.76M | Jan 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.28% | 691,003 | 5.99M | Jan 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 1.26% | 682,018 | 5.91M | Dec 30, 2025 |
